Director/PDMR Shareholding

Hikma Pharmaceuticals Plc

23 December 2024

 

Hikma Pharmaceuticals PLC

(the "Company")

LONDON, 23 December 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces it has been notified of the following transaction by a Person Discharging Managerial Responsibilities ("PDMR") of the Company.

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by A Person Discharging Managerial Responsibilities

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Disposal of Shares in Hikma Pharmaceuticals PLC
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.47	3,300
d)	Aggregated information	Price(s): £19.47 Volume(s): 3,300 Total: £64,251
e)	Date of the transaction	20 December 2024
f)	Place of the transaction	London Stock Exchange (XLON)

Helen Middlemist

Group Company Secretary
[phone]

 

END